Beyond Air® To Participate in Three Upcoming Investor Conferences
GARDEN CITY, N.Y., Sept. 16, 2022 (GLOBE NEWSWIRE) — Beyond Air, Inc. (NASDAQ:XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced that the Company is scheduled to participate in a fireside chat at the LifeSci Partners HealthTech Symposium being held virtually September 20-21, 2022. Additionally, Steve Lisi, Chairman and CEO of Beyond Air, will be presenting corporate overviews and participating in 1×1 meetings at the Ladenburg Thalmann Healthcare Conference being held Thursday, September 29, 2022 at the Sofitel Hotel New York and the Roth Inaugural Healthcare Opportunities Conference on October 6, 2022 in New York City.
Related news for (XAIR)
- Beyond Air Announces Exercise of Warrants for $3.25 Million of Gross Proceeds
- 24/7 Market News Snapshot 08 September, 2025 – Beyond Air, Inc. Common Stock (NASDAQ:XAIR)
- SaaS Pivots, AI Bets, and Green Tech Grabs, with Eyes on Innovation
- MoBot alert highlights: NASDAQ: OCTO, NASDAQ: AIRE, NASDAQ: NAKA, NASDAQ: XAIR, NASDAQ: SKYQ (09/08/25 09:00 AM)
- MoBot’s Stock Market Highlights – 09/08/25 08:00 AM